Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper – Melanoma and other skin tumours

3661 - Long-term Outcomes from the Randomized Ph 2 Study of Nivolumab (nivo) or Nivo+Ipilimumab (ipi) in Patients (pts) with Melanoma Brain Metastases (mets): Anti-PD1 Brain Collaboration (ABC)

Date

28 Sep 2019

Session

Proffered Paper – Melanoma and other skin tumours

Topics

Tumour Site

Melanoma

Presenters

Georgina Long

Citation

Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255

Authors

G.V. Long1, V.G. Atkinson2, S. Lo3, S.K. Sandhu4, M. Brown5, M. Gonzalez6, A. Guminski7, R.A. Scolyer8, L. Emmett9, A.M. Menzies1, G.A. McArthur10

Author affiliations

  • 1 Medicine, Melanoma Institute Australia, The University of Sydney, Mater Hospital, and Royal North Shore Hospital, 2065 - Sydney/AU
  • 2 Division Of Cancer Services, Princess Alexandra Hospital, University of QLD, 4102 - Woolloongabba/AU
  • 3 Melanoma Institute Australia, The University of Sydney School of Public Health, 2006 - Sydney/AU
  • 4 Division Of Medical Oncology, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 5 Translational Oncology, Royal Adelaide Hospital RAH Cancer Centre, 5000 - Adelaide/AU
  • 6 Division Of Medical Oncology, Melanoma Institute Australia, University of Sydney, 2060 - North Sydney/AU
  • 7 Medical Oncology, Royal North Shore Hospital, 2065 - St Leonards/AU
  • 8 Department Of Tissue Pathology And Diagnostic Oncology, Melanoma Institute Australia, Royal Prince Alfred Hospital, 2050 - Camperdown/AU
  • 9 Department Of Theranostics, St. Vincent's Hospital, 2010 - Darlinghurst/AU
  • 10 Cancer Medicine, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3661

Background

Preliminary data from the ABC (76 pts, med f/u 17mo) and CheckMate 204 (94 pts, med f/u 14mo) trials showed that nivo and nivo+ipi have activity in active melanoma brain metastases, with durable responses in a subset of pts. Here, we report the survival and updated response data from all pts enrolled (Nov 2014-Apr 2017) on the randomised Ph2 ABC trial (NCT02374242) of 3 cohorts of pts with active melanoma brain mets naïve to anti-PD1/PDL1/CTLA4.

Methods

Pts with asymptomatic brain mets with no prior local brain therapy were randomised to cohort A (nivo 1mg/kg + ipi 3mg/kg, Q3Wx4, then nivo 3mg/kg Q2W) or cohort B (nivo 3mg/kg Q2W). Cohort C (nivo 3mg/kg Q2W) had brain mets i) that failed local therapy, ii) with neuro symptoms and/or iii) with leptomeningeal disease. Prior BRAF inhibitor (BRAFi) was allowed. The primary endpoint was best intracranial response (ICR) ≥wk12. Secondary endpoints were best extracranial response (ECR), best overall response, IC PFS, EC PFS, overall PFS, OS, & safety.

Results

76 pts (med f/u 34 mo) were enrolled; median age 59y, 78% male. For cohorts A, B and C: elevated LDH 51%, 58% and 19%; V600 BRAF 54%, 56% and 81%; prior BRAFi 23%, 24%, 75%. The ICR/ECR in A, B and C were 51%/57%, 20%/29% and 6%/25%, respectively, with complete ICR in 26%, 16% and 0%. The 12- and 24-mo IC PFS were cohort A: 49% and 49%, B: 20% and 15% and C: 6% and 6%, and the 12- and 24-mo OS were A: 63% and 63%, B: 60% and 51% and C: 31% and 19%. ICR and 24-mo IC PFS in cohort A drug treatment naïve (n = 27) were 59% and 56%, respectively. Treatment-related AEs gd 3/4 toxicity in A, B and C were 54%, 20% and 13%, respectively. There were no treatment-related deaths. Quality of life was assessed using EQ-5D-5L, QOL C30 and BM-20 questionnaires.

Conclusions

With longer follow up, upfront ipi+nivo demonstrates durable IC responses in the majority of patients, with no new AEs. A study of upfront ipi+nivo+SRS vs ipi+nivo is planned (NCT03340129).

Clinical trial identification

NCT02374242.

Editorial acknowledgement

NIL.

Legal entity responsible for the study

Melanoma Institute Australia.

Funding

Bristol-Myers Squibb.

Disclosure

G.V. Long: Advisory / Consultancy: Aduro, Amgen, BMS, Mass-Array, Merck MSD, Novartis, ONcosec, Pierre Fabre, Roche. V.G. Atkinson: Honoraria (self): BMS, MSD, Merck Serono, Pierre Fabre, Roche, Novartis; Advisory / Consultancy: BMS, MSD, Merck Serono, Pierre Fabre, Roche, Novartis; Speaker Bureau / Expert testimony: BMS, MSD, Merck Serono, Roche, Novartis; Travel / Accommodation / Expenses: BMS, MSD, Roche, Onco-Sec. S.K. Sandhu: Honoraria (self): Janssen, Bristol-Myers Squibb, Roche/Genentech, Merck Sharp and Dohme and Merck Serono; Research grant / Funding (institution): Merck, Merck Serono, Bristol-Myers Squibb, Amgen,Tolmar; Travel / Accommodation / Expenses: Genentech, Janssen, Merck. M. Brown: Honoraria (institution): BMS. A. Guminski: Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: Merck Kga, SunPharm; Advisory / Consultancy: Eisai, Regeneron, Sandofi. R.A. Scolyer: Advisory / Consultancy: Merck, Sharp & Dohme, Novartis, Myriad, NeraCare. A.M. Menzies: Advisory / Consultancy: BMS, MSD, Novartis, Roche, Pierre Fabre. G.A. McArthur: Honoraria (institution): - Genentech/Roche - MSD - BMS - Array BioPharm - Amgen - Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.